Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cell Death and Disease (2014) 5, e1149; doi:10.1038/cddis.2014.115
- Schlagwort
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2015
- Urheber
-
Diessner, J.
Bruttel, V.
Stein, R. G.
Horn, E.
Häusler, S. F. M.
Dietl, J.
Hönig, A.
Wischhusen, J.
- URN
-
urn:nbn:de:bvb:20-opus-119884
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Diessner, J.
- Bruttel, V.
- Stein, R. G.
- Horn, E.
- Häusler, S. F. M.
- Dietl, J.
- Hönig, A.
- Wischhusen, J.
- Universität Würzburg
Entstanden
- 2015
Ähnliche Objekte (12)
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Trastuzumab emtansine: mechanisms of action and drug resistance
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Shorter course of trastuzumab: Caveat emptor
Trastuzumab administration during pregnancy: an update
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Trastuzumab emtansine: mechanisms of action and drug resistance
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Shorter course of trastuzumab: Caveat emptor
Trastuzumab administration during pregnancy: an update
Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Arzneimittel Profil Trastuzumab-Deruxtecan
Arzneimittel Profil Trastuzumab-Deruxtecan
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
Trastuzumab emtansine: mechanisms of action and drug resistance
Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
Shorter course of trastuzumab: Caveat emptor